MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer

Trial Title: MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer

NCT ID: NCT05831917

Condition: HNSCC

Conditions: Official terms:
Head and Neck Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: Radiotherapy
Description: Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles. chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles.
Arm group label: Treatment Group

Summary: Recently developed hybrid machines (MRidian®-CE approval since 2016), consisting of a linear accelerator and an integrated low-field MRI, could allow better visualization of tumor and organs at risk during patient positioning and daily treatment finally repetitive adaptation of target volumes according to changes in patient weight and tumor anatomy during the radiotherapy course. These procedures would facilitate a high-precision treatment and help reduce dose exposure of critical structures.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age 18-70 years old; 2. I-IVb stage oral cancer, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer confirmed by histopathology or cytology (AJCC 8th edition); 3. Receiving radical synchronous radiotherapy and chemotherapy; 4. According to the RECIST version 1.1 evaluation criteria, at least one measurable lesion is present; 5. ECOG PS score 0-1; 6. Hematology indicators are basically normal: white blood cell count ≥ 4 × 109/L； Absolute neutrophil count ≥ 1.5 × 109/L； Platelets ≥ 100 × 109/L； Hemoglobin ≥ 90g/L; Kidney function is basically normal: serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl)>60 mL/min (using Cockcroft Fault formula): Female CrCl=(140 age) × Body weight (kg) × 0.85 / (72 × Scr mg/dl)； Male CrCl=(140 age) × Body weight (kg) × 1.00 / (72 × Scr mg/dl) Liver function is basically normal: serum total bilirubin ≤ 1.5 × ULN； Cereal grass transaminase (AST) ≤ 2.5 × ULN； Glutamate transaminase (ALT) ≤ 2.5 × ULN； 7. Having sufficient cognitive ability to complete the questionnaire survey; 8. Able to understand and willing to sign a written informed consent form. Exclusion Criteria: 1. There is evidence of swallowing dysfunction (unrelated to HNSCC); 2. Patients who have previously received radiotherapy for the head and neck region; 3. Recurrent or metastatic patients; 4. Involvement of posterior pharyngeal wall, posterior ring, and posterior pharyngeal lymph nodes; 5. Previous tumor resection surgery or major head and neck surgery (excluding biopsy/tonsillectomy); 6. Previous tracheotomy; 7. Participated in other interventional clinical trials within 30 days prior to screening; 8. Individuals with a history of other malignant tumors (excluding cured skin basal cell carcinoma) 9. There are concurrent diseases with poor control (such as heart failure, severe lung disease, severe liver disease, mental illness, etc.); 10. Individuals who are allergic to the use of drugs or their components in this protocol; 11. Pregnant (confirmed by blood or urine HCG testing) or lactating women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment; 12. Researchers believe that it is not suitable to participate in this study; 13. Those who are unwilling to participate in this study or unable to sign an informed consent form;

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Sichuan Cancer Hospital and Research Institute

Address:
City: Chengdu
Zip: 610041
Country: China

Status: Recruiting

Contact:
Last name: Yangkun Luo

Phone: 13518161979
Email: 621199521@qq.com

Start date: January 17, 2023

Completion date: January 1, 2026

Lead sponsor:
Agency: Sichuan Cancer Hospital and Research Institute
Agency class: Other

Source: Sichuan Cancer Hospital and Research Institute

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05831917